| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcff13f8573db698307f919e6385d5c4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2503-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2503-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-42 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0695
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y30-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2007-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4761abf10d2ed7bd5ccdb23cc2aefe19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f32e6adc4c1e19bf72903b36513865f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3df0a1d963afc6c577a9aa632f4d2b7b |
| publicationDate |
2011-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8044259-B2 |
| titleOfInvention |
Determining the capability of a test compound to affect solid tumor stem cells |
| abstract |
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumor cells in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9206256-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11427591-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9945842-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9778264-B2 |
| priorityDate |
2000-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |